Skip to main content

Trends in Drug Testing Resulting From the COVID-19 Pandemic

Trends in Drug Testing Resulting From the COVID-19 Pandemic

Click here to listen


The convergence of the opioid epidemic and the coronavirus disease 2019 (COVID-19) pandemic has created new healthcare challenges. Health systems, from a system- and individual clinician-level, are more important than ever in the pursuit of addressing the epidemic within the pandemic.

In this session, Dr Gudin discusses:

  • Recently-published data by Quest that demonstrates decreased drug testing overall, with increased positivity for high-risk drugs and dangerous drug combinations
  • Tools and practices for clinicians to assess and stratify patients for potential prescription drug abuse
  • System-level strategies that employ an integrated care delivery approach, including leveraging community and diagnostics partnerships, to support impacted patient populations

Jeffrey Gudin, MD; Executive Director, Medical Affairs, Drug Monitoring & Toxicology

Dr Gudin is an active speaker and advisor whose clinical and research interests include postoperative pain management; opioid abuse, and potential solutions; and increasing clinical awareness of pain assessment and risk management. Board-certified in pain management, addiction medicine, and hospice and palliative medicine, Dr Gudin is also a medical acupuncturist. He serves as co-Editor-at-Large for Practical Pain Management.

Date: Thursday, September 02, 2021

Author(s): Gudin, J